TD Cowen Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

Posted by George Bondi on Nov 6th, 2026

United Therapeutics (NASDAQ:UTHR – Free Report) had its target price increased by TD Cowen from $675.00 to $700.00 in a report published on Thursday,Benzinga reports. TD Cowen currently has a buy rating on the biotechnology company’s stock.

UTHR has been the topic of a number of other research reports. Jefferies Financial Group restated a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $850.00 price objective on shares of United Therapeutics in a research report on Monday, October 26th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Leerink Partners boosted their target price on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a report on Thursday, October 15th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $676.40.

Check Out Our Latest Report on United Therapeutics

United Therapeutics Trading Down 7.0%

NASDAQ UTHR opened at $565.72 on Thursday. United Therapeutics has a 1 year low of $444.04 and a 1 year high of $614.23. The company has a market cap of $24.26 billion, a PE ratio of 21.35, a PEG ratio of 4.41 and a beta of 0.49. The stock’s 50-day moving average price is $533.31 and its two-hundred day moving average price is $532.95.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm had revenue of $832.50 million during the quarter, compared to analyst estimates of $781.14 million. During the same quarter in the previous year, the business earned $7.16 earnings per share. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. Research analysts forecast that United Therapeutics will post 26.09 EPS for the current fiscal year.

United Therapeutics declared that its Board of Directors has authorized a share repurchase plan on Thursday, October 22nd that allows the company to buy back $2 billion in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $598.67, for a total value of $4,968,961.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $27,043,121.24. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,723 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $611.06, for a total transaction of $1,052,856.38. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $198,254,139.58. The trade was a 0.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 401,528 shares of company stock valued at $212,977,429 over the last three months. 8.60% of the stock is owned by insiders.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of UTHR. Toth Financial Advisory Corp boosted its position in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors acquired a new position in United Therapeutics in the 2nd quarter worth about $30,000. Gen Wealth Partners Inc acquired a new position in United Therapeutics in the 3rd quarter worth about $34,000. Caitlin John LLC acquired a new position in United Therapeutics in the 2nd quarter worth about $37,000. Finally, International Assets Investment Management LLC raised its stake in shares of United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: Several analysts raised price targets and maintained bullish ratings: BTIG lifted its target to $768, RBC to $725, and TD Cowen to $700. BTIG cited Tyvaso momentum in its positive outlook. Analyst outlook and Tyvaso momentum
Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating estimates of about $781 million. The company also announced a buydown of a royalty tied to ralinepag, potentially improving the economics of the therapy. Third-quarter results Ralinepag royalty announcement
Negative Sentiment: Adjusted earnings were $5.71 per share, below the roughly $6.01 analyst consensus and down from $7.16 a year earlier. The earnings miss and year-over-year decline in EPS may temper the positive revenue growth news. Quarterly earnings miss
Negative Sentiment: CEO Martine Rothblatt and EVP Paul Mahon reported stock sales. Insider sales can concern investors, although both executives retained substantial holdings after the transactions. CEO sale filing EVP sale filing

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.